Research programme: small molecule therapeutics - Praxis/University of Florida
Latest Information Update: 28 May 2026
At a glance
- Originator Praxis Precision Medicines; University of Florida
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 28 May 2026 No recent reports of development identified for research development in Neurological-disorders in USA
- 30 Apr 2022 Praxis enters into a collaboration with the University of Florida for small molecules targeting SYNGAP1
- 30 Apr 2022 Early research in Neurological disorders in USA (unspecified route) before April 2022